|
Overall survival
| |
Univariate analysis
|
Multivariate analysis
|
|
Sex (male < female)
|
153/163
|
0.70 (0.42–1.08)
|
0.104
| | |
|
Age (Over 40 < Under 40)
|
141/175
|
0.56 (0.35–0.91)
|
0.019
|
0.61 (0.38–0.99)
|
0.043
|
|
FNCLCC grade (3 < 2)
|
304/12
|
0.68 (0.09–4.93)
|
0.704
| | |
|
Subtype (Unclassified < Biphasic)
|
74/89
|
0.57 (0.27–1.21)
|
0.143
| | |
|
Subtype (Monophasic < Biphasic)
|
153/89
|
0.82 (0.45–1.51)
|
0.529
| | |
|
Depth (Superficial < Deep)
|
45/271
|
0.59 (0.24–1.48)
|
0.263
| | |
|
Tumor size (Under 5 cm < Over 5 cm)
|
117/199
|
0.73 (0.42–1.29)
|
0.277
| | |
|
Tumor location (Upper < Lower extremity)
|
56/160
|
0.81 (0.47–1.41)
|
0.811
| | |
|
Tumor location (Trunk+head and neck < Lower extremity)
|
100/216
|
0.81 (0.39–1.68)
|
0.813
| | |
|
Surgical margin (Marginal < Wide)
|
35/268
|
0.16 (0.07–0.36)
|
< 0.01
|
0.18 (0.08–0.38)
|
< 0.01
|
|
Surgical margin (Intralesional < Wide)
|
13/268
|
0.29 (0.11–0.79)
|
0.016
|
0.30 (0.11–0.78)
|
0.013
|
|
Adjuvant radiotherapy (Yes < No)
|
56/260
|
0.58 (0.32–0.90)
|
0.018
| | |
|
Perioperative chemotherapy (Yes < No)
|
215/101
|
0.64 (0.35–1.14)
|
0.114
| | |
|
Neoadjuvant (Yes < No)
|
165/151
|
0.73 (0.28–1.88)
|
0.508
| | |
|
Adjuvant (Yes < No)
|
131/185
|
0.48 (0.16–1.42)
|
0.182
| | |
|
Local control
| |
Univariate analysis
|
Multivariate analysis
|
|
Sex (male < female)
|
153/163
|
0.94 (0.42–2.49)
|
0.940
| | |
|
Age (Over 40 < Under 40)
|
141/175
|
0.95 (0.39–2.32)
|
0.910
| | |
|
FNCLCC grade (3 < 2))
|
304/12
|
0.05a
|
0.636
| | |
|
Subtype (Unclassified < Biphasic)
|
74/89
|
0.58 (0.17–2.70)
|
0.580
| | |
|
Subtype (Monophasic < Biphasic)
|
153/89
|
0.82 (0.32–3.12)
|
0.990
| | |
|
Depth (Superficial < Deep)
|
45/271
|
0.33 (0.04–2.49)
|
0.284
| | |
|
Tumor size (Under 5 cm < Over 5 cm)
|
117/199
|
0.61 (0.22–1.70)
|
0.340
| | |
|
Tumor location (Upper < Lower extremity)
|
56/160
|
0.76 (0.28–2.05)
|
0.592
| | |
|
Tumor location (Trunk+head and neck < Lower extremity)
|
100/216
|
0.67 (0.17–2.58)
|
0.557
| | |
|
Surgical margin (Marginal < Wide)
|
35/268
|
0.12 (0.04–0.36)
|
0.011
|
0.14 (0.05–0.44)
|
0.001
|
|
Surgical margin (Intralesional < Wide)
|
13/268
|
0.08 (0.01–0.70)
|
0.022
|
0.09 (0.01–0.84)
|
0.035
|
|
Adjuvant radiotherapy (Yes < No)
|
56/260
|
0.24 (0.10–0.58)
|
0.001
| | |
|
Perioperative chemotherapy (Yes < No)
|
215/101
|
0.37 (0.12–1.12)
|
0.171
| | |
|
Neoadjuvant (Yes < No)
|
165/151
|
0.97 (0.40–2.32)
|
0.936
| | |
|
Adjuvant (Yes < No)
|
131/185
|
0.55 (0.20–1.51)
|
0.248
| | |
|
Distal recurrent survival
| |
Univariate analysis
|
Multivariate analysis
|
|
Sex (male < female)
|
153/163
|
0.60 (0.36–1.01)
|
0.053
|
NS
| |
|
Age (Over 40 < Under 40)
|
141/175
|
0.56 (0.35–0.90)
|
0.016
|
0.63 (0.39–1.03)
|
0.06
|
|
FNCLCC grade (3 < 2))
|
304/12
|
0.43 (0.06–3.13)
|
0.407
| | |
|
Subtype (Unclassified < Biphasic)
|
74/89
|
0.57 (0.27–1.24)
|
0.160
| | |
|
Subtype (Monophasic < Biphasic)
|
153/89
|
0.86 (0.46–1.61)
|
0.640
| | |
|
Depth (Superficial < Deep)
|
45/271
|
0.53 (0.21–1.31
|
0.284
| | |
|
Tumor size (Under 5 cm < Over 5 cm)
|
117/199
|
0.62 (0.35–1.11)
|
0.340
| | |
|
Tumor location (Upper < Lower extremity)
|
56/160
|
0.80 (0.45–2.05)
|
0.592
| | |
|
Tumor location (Trunk+head and neck < Lower extremity)
|
100/216
|
0.81 (0.39–1.70)
|
0.557
| | |
|
Postoperative local recurrence (Yes < No)
|
69/247
|
0.33 (0.16–0.71)
|
0.004
|
0.30 (0.17–0.90)
|
0.027
|
|
Surgical margin (Marginal < Wide)
|
35/268
|
0.21 (0.08–0.54)
|
0.001
|
0.31 (0.11–0.85)
|
0.023
|
|
Surgical margin (Intralesional < Wide)
|
13/268
|
0.46 (0.15–1.38)
|
0.105
|
0.71 (0.21–2.34)
|
0.571
|
|
Adjuvant radiotherapy (Yes < No)
|
56/260
|
0.44 (0.26–0.73)
|
0.002
| | |
|
Perioperative chemotherapy (Yes < No)
|
215/101
|
0.60(0.33–1.08)
|
0.089
| | |
|
Neoadjuvant (Yes < No)
|
165/151
|
0.86(0.54–1.40)
|
0.562
| | |
|
Adjuvant (Yes < No)
|
131/185
|
0.62(0.37–1.05)
|
0.073
| | |
